Efficacy and safety of a recombinant factor IX (Bax326)1 in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open‐label, uncontrolled, multicentre, phase III study. (3rd April 2014)

• Record Type: Journal Article
• Authors: Windyga, J.; Lissitchkov, T.; Stasyshyn, O.; Mamonov, V.; Ghandehari, H.; Chapman, M.; Fritsch, S.; Wong, W.‐Y.; Pavlova, B. G.; Abbuehl, B. E.
• Is Part Of: Haemophilia. Volume 20:Number 5(2014:Sep.)
• Page Start: 651
• Page End: 658
• Publication Date: 2014-04-03
• Subjects: haemophilia B -- previously treated patients -- rFIX (Rixubis) -- surgical procedures; Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.12419
• Languages: English
• ISSNs: 1351-8216

Abstract

Summary: Haemostatic management of haemophilia B patients undergoing surgery is critical to patient safety. The aim of this ongoing prospective trial was to investigate the haemostatic efficacy and safety of a recombinant factor IX (rFIX) (Bax326)1 in previously treated subjects (12–65 years, without history of FIX inhibitors) with severe or moderately severe haemophilia B, undergoing surgical, dental or other invasive procedures. Haemostatic efficacy was assessed according to a predefined scale. Blood loss was compared to the average and maximum blood loss predicted preoperatively. Haemostatic FIX levels were achieved peri‐ and postoperatively in 100% of subjects ( n = 14). Haemostasis was 'excellent' intraoperatively in all patients and postoperatively in those without a drain, and 'excellent' or 'good' at the time of drain removal and day of discharge in those with a drain employed. Following the initial dose, the mean FIX activity level rose from 6.55% to 107.58% for major surgeries and from 3.60% to 81.4% for minor surgeries. Actual vs. predicted blood loss matched predicted intraoperative blood loss but was equal to or higher than (but less than 150%) the maximum predicted postoperative blood loss reflecting the severity of procedure and FIX requirements. There were no related adverse events, severe allergic reactions or thrombotic events. There was no evidence that BAX326 increased the risk of inhibitor or binding antibody development to FIX. BAX326 was safe and effective for peri‐operative management of 14 subjects with severe and moderately severe haemophilia B.